Description
A potent, selective p38alpha MAPK inhibitor with IC50 of 9nM; displays 10-fold selectivity for p38alpha over p38beta, >2,000-fold selectivity over a panel of 20 other kinases, including other MAP kinases; decreases apoptosis in MDS CD34+ progenitors and leads to dose-dependant increases in erythroid and myeloid colony formation; enhances the ability ofmg132 and bortezomib to induce the apoptosis of MM cells, and inhibits tumor growth in vivo. Rheumatoid Arthritis Phase 2 Discontinued